Eli Lilly posted first-quarter revenue of $19.8 billion, a 56% year-over-year jump that cleared analyst expectations by roughly $2 billion. Adjusted earnings per share came in at $8.55, beating consensus by $1.76. The standout driver was its GLP-1 drug portfolio — Mounjaro alone grew 125% year-over-year, and Zepbound sales nearly doubled — prompting management to raise full-year guidance.
This is one of the most consequential earnings beats in large-cap pharma in years, and it reinforces Eli Lilly's position as the dominant GLP-1 franchise. Investors holding LLY directly benefit, but the ripple effects hit broader healthcare ETFs, competitor obesity drug plays like Novo Nordisk, and any company in the GLP-1 supply chain — from medical devices to food companies facing long-term demand risk.
May 2025: Novo Nordisk Q1 earnings (direct GLP-1 competitor comparison). June 2025: FDA decisions on next-generation obesity drug approvals. July 30, 2025: Eli Lilly Q2 earnings report.
Full analysis · Subscribers
The deep dive (bull case, bear case, and the data point that decides which side wins), the cause-and-effect chain behind the move, plain-English explainers for every block, and the live update timeline (1 update so far).
Aggregated reads dozens of sources in five languages and turns the day into plain-English cards like this one.
Educational analysis of public information, not investment advice. Report an error · Corrections policy
← Today's brief